Clinical trial
A Single/Multiple Dose Escalation, Open-Labeled, Phase I Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB1001 in Patients With Acute Optic Neuropathy
NCT06506305 is registered in ClinicalTrials.gov with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single/Multiple Dose Escalation, Open-Labeled, Phase I Clinical Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB1001 in Patients With Acute Optic Neuropathy
- Lead sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- August 15, 2024
- Completion date
- October 31, 2026
- Enrollment
- 59 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
apac - acute primary angle closure, glaucoma, angle-closure, naion - non-arteritic ischemic optic neuropathy, optic neuropathy